ESO08 Slides 25thapril

Guidelines for Management of Ischaemic Stroke 2008
The European Stroke Organization - ESO Executive Committee and Writing Committee
MISSION OF ESO
To reduce the incidence and burden of stroke by changing the way stroke is viewed and treated in Europe
Guidelines Ischaemic Stroke 2008
ESO Guidelines 2008

Content: Education, Referral and Emergency room Stroke Unit Imaging and Diagnostics Prevention General Treatment Acute Treatment Management of Complications Rehabilitation
ESO Writing Committee

Chair: Werner Hacke, Heidelberg, Germany
Co-Chairs: Marie-Germaine Bousser, Paris, France Gary Ford, Newcastle, UK

Education, Referral and Emergency room Co-Chairs: Michael Brainin, Krems, Austria; Jos Ferro, Lisbon, Portugal Members: Charlotte Cordonnier, Lille, France; Heinrich P. Mattle, Bern, Switzerland; Keith Muir, Glasgow, UK; Peter D. Schellinger, Erlangen, Germany
Stroke Units Co-Chairs: Hans-Christoph Diener, Essen, Germany; Peter Langhorne, Glasgow, UK Members: Antony Davalos, Barcelona, Spain; Gary Ford, Newcastle, UK; Veronika Skvortsova, Moscow, Russia

Imaging and Diagnostics Co-Chairs: Michael Hennerici, Mannheim, Germany; Markku Kaste, Helsinki, Finland Members: Hugh S. Markus, London, UK; E. Bernd Ringelstein, Mnster, Germany; Rdiger von Kummer, Dresden, Germany; Joanna Wardlaw, Edinburgh, UK
Prevention Co-Chairs: Phil Bath, Nottingham, UK; Didier Leys, Lille, France Members: lvaro Cervera, Barcelona, Spain; Lszl Csiba, Debrecen, Hungary; Jan Lodder, Maastricht, The Netherlands; Nils Gunnar Wahlgren, Stockholm

General Treatment Co-Chairs: Christoph Diener, Essen, Germany; Peter Langhorne, Glasgow, UK Members: Antony Davalos, Barcelona, Spain; Gary Ford, Newcastle, UK; Veronika Skvortsova, Moscow, Russia Acute Treatment and Treatment of Complications Co-Chairs: Angel Chamorro, Barcelona, Spain; Bo Norrving, Lund, Sweden Members: Valerica Caso, Perugia, Italy; Jean-Louis Mas, Paris, France; Victor Obach, Barcelona, Spain; Peter A. Ringleb, Heidelberg, Germany; Lars Thomassen, Bergen, Norway

Rehabilitation Co-Chairs: Kennedy Lees, Glasgow, UK; Danilo Toni, Rome, Italy Members: Stefano Paolucci, Rome, Italy; Juhani Sivenius, Kuopio, Finland; Katharina Stibrant Sunnerhagen, Gteborg, Sweden; Marion F. Walker, Nottingham, UK; Substantial assistance: Yvonne Teuschl, Isabel Henriques, Terence Quinn
Definitions of Levels of Evidence

Level A Established as useful/predictive or not useful/predictive for a diagnostic measure or established as effective, ineffective or harmful for a therapeutic intervention; requires at least one convincing Class I study or at least two consistent, convincing Class II studies. Established as useful/predictive or not useful/predictive for a diagnostic measure or established as effective, ineffective or harmful for a therapeutic intervention; requires at least one convincing Class II study or overwhelming Class III evidence. Established as useful/predictive or not useful/predictive for a diagnostic measure or established as effective, ineffective or harmful for a therapeutic intervention; requires at least two Class III studies. Recommended best practice based on the experience of the guideline development group. Usually based on Class IV evidence indicating large clinical uncertainty, such GCP points can be useful for health workers.
Level B
Level C
Good Clinical Practice (GCP)
Classification of Evidence
Evidence classification scheme for a therapeutic intervention Class I An adequately powered, prospective, randomized, controlled clinical trial with masked outcome assessment in a representative population or an adequately powered systematic review of prospective randomized controlled clinical trials with masked outcome assessment in representative populations. Prospective matched-group cohort study in a representative population with masked outcome assessment or a randomized, controlled trial in a representative population that lacks one criterion for class I evidence. All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome assessment is independent of patient treatment. Evidence from uncontrolled studies, case series, case reports, or expert opinion.
Class II
Class III
Class IV
Classification of Evidence
Evidence classification scheme for a diagnostic measure Class I A prospective study in a broad spectrum of persons with the suspected condition, using a gold standard for case definition, where the test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy. A prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by gold standard) compared to a broad spectrum of controls, where test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy. Evidence provided by a retrospective study where either persons with the established condition or controls are of a narrow spectrum, and where test is applied in a blinded evaluation. Evidence from uncontrolled studies, case series, case reports, or expert opinion.
Class II
Class III
Class IV
ESO Guidelines 2008

Stroke as an Emergency
Education, Referral, Emergency management
Background
Stroke is the most important cause of morbidity and long term disability in Europe1 Demographic changes are likely to result in an increase in both incidence and prevalence
Stroke is also the second most common cause of dementia, the most frequent cause of epilepsy in the elderly, and a frequent cause of depression2,3
1: Lopez AD et al. Lancet (2006) 367:1747-1757 2: Rothwell PM et al. Lancet (2005) 366:1773-1783 3: O'Brien JT et al. Lancet Neurol (2003) 2:89-98
Background
Stroke is a medical and occasionally a surgical emergency The majority of ischaemic stroke patients do not reach the hospital quickly enough
The delay between stroke onset and hospital admission is;

reduced if the Emergency Medical Systems (EMS) are used increased if doctors outside the hospital are consulted first
Emergency care in acute stroke depends on a four-step chain:

Rapid recognition of, and reaction to, stroke signs and symptoms Immediate EMS contact and priority EMS dispatch
Priority transport with notification of the receiving hospital

Immediate emergency room triage, clinical, laboratory and imaging evaluation, accurate diagnosis, and administration of appropriate treatments at the receiving hospital.
Delays during acute stroke management have been identified at three different levels1
at the population level, due to failure to recognize the symptoms of stroke and contact emergency services at the level of the emergency services and emergency physicians, due to a failure to prioritize transport of stroke patients at the hospital level, due to delays in neuroimaging and inefficient in-hospital care
1:Kwan J et al. Age Ageing (2004) 33:116-121
Education
Recommendations
Educational programmes to increase awareness of stroke at the population level are recommended (Class II, Level B) Educational programmes to increase stroke awareness among professionals (paramedics, emergency physicians) are recommended (Class II, Level B)
Referral
Recommendations (1/2)
Immediate EMS contact and priority EMS dispatch are recommended (Class II, Level B) Priority transport with advance notification of the receiving hospital is recommended (Class III, Level B)
Suspected stroke victims should be transported without delay to the nearest medical centre with a stroke unit that can provide ultra-early treatment (Class III, Level B)
Patients with suspected TIA should be referred without delay to a TIA clinic or a stroke unit (Class III, Level B)
Referral
Dispatchers and ambulance personnel should be trained to recognise stroke using simple instruments such as the Face-Arm-Speech-Test (Class IV, GCP) Immediate emergency room triage, clinical, laboratory and imaging evaluation, accurate diagnosis, therapeutic decision and administration of appropriate treatments are recommended (Class III, Level B) In remote or rural areas helicopter transfer and telemedicine should be considered to improve access to treatment (Class III, Level C)
Emergency Management
The time window for treatment of patients with acute stroke is narrow
Acute emergency management of stroke requires parallel processes operating at different levels of patient management
Acute assessment of neurological and vital functions parallels the treatment of acutely life-threatening conditions
Time is the most important factor
The initial examination should include

Observation of breathing and pulmonary function and concomitant heart disease Assessment of blood pressure and heart rate Determination of arterial oxygen saturation
Blood samples for clinical chemistry, coagulation and haematology studies

Observation of early signs of dysphagia
Targeted neurological examination

Careful medical history focussing on risk factors for arteriosclerosis and cardiac disease
Ancillary Diagnostic Tests

In all patients
Brain Imaging: CT or MRI
Diagnostics
ECG Laboratory Tests Complete blood count and platelet count, prothrombin time or INR, PTT Serum electrolytes, blood glucose CRP or sedimentation rate
Hepatic and renal chemical analysis
Ancillary Diagnostic Tests

In selected patients
Duplex / Doppler ultrasound
Diagnostics
MRA or CTA Diffusion and perfusion MR or perfusion CT Echocardiography, Chest X-ray Pulse oximetry and arterial blood gas analysis Lumbar puncture EEG
Toxicology screen
Recommendations
Organization of pre-hospital and in-hospital pathways and systems for acute stroke patients is recommended (Class III, Level C) All patients should receive brain imaging, ECG, and laboratory tests. Additional diagnostic examinations are necessary in selected patients (Class IV, GCP)
ESO Guidelines 2008

Stroke Unit
A stroke unit
Is a dedicated and geographically defined part of a hospital that takes care of stroke patients Has specialised staff with coordinated multidisciplinary expert approach to treatment and care
Comprises core disciplines: medical, nursing, physiotherapy, occupational therapy, speech and language therapy, social work 1
1:Langhorne P et al. Age Ageing (2002) 31:365-371
Stroke Unit
Typical components of stroke units include

Assessment Medical assessment and diagnosis, early assessment of nursing and therapy needs Early management policies
Early mobilisation, prevention of complications, treatment of hypoxia, hyperglycaemia, pyrexia and dehydration Ongoing rehabilitation policies
Coordinated multidisciplinary team care Early assessments of needs after discharge
Stroke Unit
Treatment at a stroke unit compared to treatment in a general ward1

reduces mortality (absolute risk reduction of 3%) reduces dependency (5%) reduces need for institutional care (2%)
All types of patients, irrespective of gender, age, stroke subtype and stroke severity, appear to benefit from treatment in stroke units1
1:Stroke Unit Trialists' Collaboration Cochrane Rev (2007)
Stroke Services and Stroke Units

Recommendations
All stroke patients should be treated in a stroke unit (Class I, Level A) Healthcare systems must ensure that acute stroke patients can access high technology medical and surgical stroke care when required (Class III, Level B) The development of clinical networks, including telemedicine, is recommended to expand the access to high technology specialist stroke care (Class II, Level B)
ESO Guidelines 2008

Emergency Diagnostic Tests

Differentiate between different types of stroke
Assess the underlying cause of brain ischaemia
Diagnostics
Assess prognosis
Provide a basis for physiological monitoring of the stroke patient Identify concurrent diseases or complications associated with stroke Rule out other brain diseases

Cranial Computed Tomography (CT)
Immediate plain CT scanning distinguishes reliably between haemorrhagic and ischaemic stroke
Diagnostics
Detects signs of ischaemia as early as 2 h after stroke onset1
Helps to identify other neurological diseases (e.g. neoplasms)

Most cost-effective strategy for imaging acute stroke patients2
1: von Kummer R et al. Radiology (2001) 219:95-100 2: Wardlaw J et al. Stroke (2004) 35:2477-2483

Magnetic Resonance Imaging (MRI)
Diffusion-weighted MRI (DWI) is more sensitive for detection of early ischaemic changes than CT
Diagnostics
DWI can be negative in patients with definite stroke1 Identifies ischaemic lesions in the posterior fossa reliably Detects even small intracerebral haemorrhages reliably on T2* sequences
MRI is particularly important in acute stroke patients with unusual presentations

1: Ay H et al. Cerebrovasc Dis (2002) 14:177-186 Guidelines Ischaemic Stroke 2008

Mismatch Concept
Diagnostics
Mismatch between tissue abnormal on DWI and tissue with reduced perfusion may reflect tissue at risk of further ischaemic damage1 There is disagreement on how to best identify irreversible ischaemic brain injury and to define critically impaired blood flow2 There is no clear evidence that patients with particular perfusion patterns are more or less likely to benefit from thrombolysis3
1: Jansen O et al. Lancet (1999) 353:2036-2037 2: Kane I et al. Stroke (2007) 38:3158-3164 3: Albers GW et al. Ann Neurol (2006) 60:508-517

Ultrasound studies
Cerebrovascular ultrasound is fast and non-invasive and can be administered using portable machines.
Diagnostics
It is therefore applicable to patients unable to cooperate with MRA or CTA1
Combinations of ultrasound imaging techniques and MRA can produce excellent results that are equal to Digital subtraction angiography (DSA)2
1: Allendrfer J et al. Lancet Neurology (2005) 5:835-840 2: Nederkoorn P et al. Stroke (2003) 34:1324-1332

Imaging in TIA-patients
Up to 10% recurrence risk in the first 48 hours1
Diagnostics
Simple clinical scoring systems can be used to identify patients at particularly high risk1 Up to 50% of patients with TIAs have acute ischaemic lesions on DWI. These patients are at increased risk of early recurrent disabling stroke2 There is currently no evidence that DWI provides better stroke prediction than clinical risk scores3
1: Rothwell P et al. Lancet Neurol (2005) 5:323-331 2: Coutts S et al. Ann Neurol (2005) 57:848-854 3: Redgrave J et al. Stroke (2007) 38:1482-1488

Electrocardiogram (ECG)
Cardiac abnormalities are common in acute stroke patients1
Diagnostics
Arrhythmias may induce stroke, stroke may cause arrhythmias
Holter monitoring is superior to routine ECG for the detection of atrial fibrillation (AF)2
It is unclear whether continuous ECG recording at the bedside is equivalent to Holter monitoring for the detection of AF
1: Christensen H et al. Neurol Sci (2005) 234:99 103 2: Gunalp M et al. Adv Ther (2006) 23:854-60 Guidelines Ischaemic Stroke 2008

Echocardiography (TTE / TOE)
Echocardiography can detect many potential causes of stroke1
Diagnostics
It is particularly required in patients with history of cardiac disease, ECG pathologies, suspected source of embolism, suspected aortic disease, suspected paradoxical embolism Transoesophageal echocardiography (TOE) might be superior to transthoracic echocardiography (TTE) for the detection of potential cardiac sources of embolism2
1: Lerakis S et al. Am J Med Sci (2005) 329:310-6 2: de Bruijn SF et al. Stroke (2006) 37:2531-4 Guidelines Ischaemic Stroke 2008

Laboratory tests
Haematology (RBC, WBC, platelet count)
Diagnostics
Basic clotting parameters Electrolytes Renal and hepatic chemistry Blood Glucose CRP, sedimentation rate
Diagnostic Imaging
Recommendations
In patients with suspected TIA or stroke, urgent cranial CT (Class I), or alternatively MRI (Class II), is recommended (Level A) If MRI is used, the inclusion of diffusion weighted imaging (DWI) and T2*-weighted gradient echo sequences is recommended (Class II, Level A) In patients with TIA, minor stroke, or early spontaneous recovery immediate diagnostic work-up, including urgent vascular imaging (ultrasound, CT-angiography, or MR angiography) is recommended (Class I, Level A)
Other Diagnostics
Diagnostics
In patients with acute stroke and TIA, early evaluation of physiological parameters, routine blood tests, and electrocardiography (ECG) is recommended (Class I, Level A)
All acute stroke and TIA patients should have a 12channel ECG. Continuous ECG recording is recommended for ischaemic stroke and TIA patients (Class I, Level A)
Other Diagnostics
Diagnostics
For stroke and TIA patients seen after the acute phase, 24-hour Holter ECG monitoring should be performed when arrhythmias are suspected and no other causes of stroke are found (Class I, Level A)
For all stroke and TIA patients, a sequence of blood tests is recommended
Echocardiography is recommended in selected patients (Class III, Level B)
ESO Guidelines 2008

Primary Prevention
Content
Management of vascular risk factors
Primary Prevention
Antithrombotic therapy Carotid surgery and angioplasty
Vascular Risk Factors

Conditions and lifestyle characteristics identified as a risk factors for stroke
Primary Prevention
High blood pressure Atrial fibrillation Diabetes mellitus Carotid artery disease Myocardial infarction
High Cholesterol Hyper-homocysteinaemia Smoking Heavy alcohol use Physical inactivity Obesity
High blood pressure (BP)

Background
Primary Prevention
High blood pressure (>120/80mmHg) is the most important and prevalent modifiable risk factor for stroke Significant reduction of stroke incidence with a decrease in BP1 No class of antihypertensive is clearly superior
LIFE: lorsatan is superior to atenolol2 ALLHAT: chlorthalidone is more effective than amlodipine and lisinopril3
1: Neal B et al. Lancet (2000) 356:1955-64 2: Dahlof B et al. Lancet (2002) 359:995-1003. 3: Mancia G et al. Eur Heart J (2007) 28:1462-536
Diabetes mellitus
Background
Independent risk factor for ischaemic stroke
Primary Prevention
Improving glucose control may not reduce stroke1 BP in patients with diabetes should be <130/80mmHg2 Statin treatment reduces the risk of major vascular events, including stroke3 Elevated blood glucose in the early phase of stroke is associated with death and poor recovery
1: Turner RC et al. JAMA (1999) 281:2005-12 2: Mancia GJ: Hypertens Suppl (2007) 25:S7-12 3: Sever PS et al. Diabetes Care (2005) 28:1151-7
High Cholesterol
Background
Primary Prevention
Statin treatment reduces the incidence of stroke from 3.4% to 2.7%1 No significant effect for prevention of fatal stroke1 Heart Protection Study found an excess of myopathy of one per 10,000 patients per annum2 No data support statin treatment in patients with LDLcholesterol <150 mg/dl (3.9 mmol/l)
1: Amarenco P et al.: Stroke (2004) 35:2902-2909 2: HPS Group: Lancet (2002) 360:7-22.
Cigarette Smoking
Background
Primary Prevention
Independent risk factor for ischaemic stroke in men and women 2-3 fold increased risk compared to non-smokers1 Spousal cigarette smoking may be associated with an increased stroke risk2 50% risk reduction by 2 years after stopping smoking3
1: Shinton R et al.: BMJ (1989) 298:789-94. 2: Qureshi A et al.: Stroke (2005) 36:74-76 3: Colditz GA et al.: N Engl J Med (1988) 318:937-41.
Alcohol Consumption
Background
Primary Prevention
Increased risk for both ischaemic (RR 1.69) and haemorrhagic stroke (RR 2.18) with heavy alcohol consumption (>60g/day)1 BP elevation might be a reasonable explanation3
Light alcohol consumption (<12g/day) associated with reduced ischaemic (RR 0.80) and haemorrhagic stroke1
Red wine consumption carries the lowest risk2
1: Reynolds K et al.: JAMA (2003) 289:579-88 2: Mukamal K et al.: Ann Intern Med (2005) 142:11-19 3: Bazzano LA et al.: Ann Neurol (2007)
Physical Activity
Background
Primary Prevention
Regular exercise (at least 3x30min/week) is associated with a decreased risk of stroke Physically active individuals have a lower risk of stroke or death than those with low activity (RR 0.73)1
This is mediated, in part, through beneficial effects on body weight, blood pressure, serum cholesterol, and glucose tolerance2
1: Lee C et al.: Stroke (2003) 34:2475-2481 2: Deplanque D et al.: Neurology (2006) 67:1403-1410)
Body Weight, Diet, Nutrition

Background
Primary Prevention
High body mass index (BMI 25) increases risk of stroke in men and women1 Abdominal adiposity is a risk factor for stroke in men but not women2
A randomized trial in women found no effect of dietary interventions to reduce the incidence of stroke3
Tocopherol and beta carotene supplementation do not reduce the risk of stroke. Vitamin E might increase mortality when used at high-dose (400 IU/d)
1: Kurth T et al.: Circulation (2005) 111:1992-1998 2: Hu G et al.: Arch Intern Med (2007) 167:1420-1427 3: Howard B et al.: JAMA (2006) 295:655-666
Hormone Replacement Therapy

Background
Primary Prevention
Stroke rates rise rapidly in women after the menopause Hormone replacement therapy in postmenopausal women is associated with an 44% increased risk of stroke1
1: Gabriel S et al.: Cochrane Review (2005) CD002229
Risk Factor Management

Primary Prevention
Blood pressure should be checked regularly. High blood pressure should be managed with lifestyle modification and individualized pharmacological therapy (Class I, Level A) aiming at normal levels of 120/80 mmHg (Class IV, GCP)

Primary Prevention
Blood glucose should be checked regularly. Diabetes should be managed with lifestyle modification and individualized pharmacological therapy (Class IV, Level C).
In diabetic patients, high blood pressure should be managed intensively (Class I, Level A) aiming for levels below 130/80 mmHg (Class IV, Level C). Where possible, treatment should include an angiotensin converting enzyme inhibitor or angiotensin receptor antagonist (Class I, Level A)

Primary Prevention
Blood cholesterol should be checked regularly. High blood cholesterol (e.g. LDL>150mg/dl [3,9mMol/l]) should be managed with lifestyle modification (Class IV, Level C) and a statin (Class I, Level A)
Cigarette smoking should be discouraged (Class III, Level B)

Heavy use of alcohol should be discouraged (Class III, Level B) Regular physical activity is recommended (Class III, Level B)

Primary Prevention
A diet low in salt and saturated fat, high in fruit and vegetables and rich in fibre is recommended (Class III, Level B) Subjects with an elevated body mass index are recommended to take a weight-reducing diet (Class III, Level B) Antioxidant vitamin supplements are not recommended (Class I, Level A) Hormone replacement therapy is not recommended for the primary prevention of stroke (Class I, Level A)
Antithrombotic Therapy
Background
Primary Prevention
In low risk persons low dose aspirin reduced coronary events, but not stroke1 In women over 45 years aspirin reduces the risk of ischaemic stroke (OR 0.76; 95%CI 0.63-0.93) 2
Aspirin reduces MI in patients with asymptomatic carotid artery disease3
1: Bartolucci A et al.: Am J Cardiol (2006) 98:746-750 2: Berger J et al.: JAMA (2006) 295:306-313 3: Hobson R, 2nd et al.: J Vasc Surg (1993) 17:257-263
Atrial fibrillation (AF)

Background
Average stroke rate of 5% per year
Primary Prevention
Aspirin reduces stroke (RR 0.78) in patients with nonvalvular AF1 Warfarin (INR 2.0-3.0) is more effective than aspirin at reducing stroke (RR 0.36; 95%CI 0.26-0.51)1 Combination of aspirin and clopidogrel is less effective than warfarin and has a similar bleeding rate2
1: Hart RG et al.: Ann Intern Med (2007) 146:857-867 2: Connolly S et al.: Lancet (2006) 367:1903-1912
Atrial fibrillation (AF)

Background
Anticoagulation with an INR below 2.0 is not effective
Primary Prevention
Increased risk for bleeding complications with an INR > 3.5 Patients <65 years of age with lone AF (without other risk factors) are at low risk, whereas patients older than 65 years are at a higher risk for embolic stroke Anticoagulation can be safe and effective in older individuals1, 2
1: Rash A et al.: Age Ageing (2007) 36:151-156 2: Mant J et al.: Lancet (2007) 370:493-503
Primary Prevention
Low-dose aspirin is recommended in women aged 45 years or more who are not at increased risk for intracerebral haemorrhage and who have good gastrointestinal tolerance; however, its effect is very small (Class I, Level A) Low-dose aspirin may be considered in men for the primary prevention of myocardial infarction; however, it does not reduce the risk of ischaemic stroke (Class I, Level A)
Primary Prevention
Antiplatelet agents other than aspirin are not recommended for primary stroke prevention (Class IV, GCP) Aspirin may be recommended for patients with nonvalvular AF who are younger than 65 years and free of vascular risk factors (Class I, Level A) Unless contraindicated, either aspirin or an oral anticoagulant (international normalized ratio [INR] 2.03.0) is recommended for patients with non-valvular AF who are aged 65-75 years and free of vascular risk factors (Class I, Level A) Guidelines Ischaemic Stroke 2008
Primary Prevention
Unless contraindicated, an oral anticoagulant (INR 2.0 3.0) is recommended for patients with non-valvular AF who are aged >75, or who are younger but have risk factors such as high blood pressure, left ventricular dysfunction, or diabetes mellitus (Class I, Level A)
Primary Prevention
Patients with AF who are unable to receive oral anticoagulants should be offered aspirin (Class I, Level A) Patients with AF who have mechanical prosthetic heart valves should receive long-term anticoagulation with a target INR based on the prosthesis type, but not less than INR 23 (Class II, Level B) Low dose aspirin is recommended for patients with asymptomatic internal carotid artery (ICA) stenosis >50% to reduce their risk of vascular events (Class II, Level B)
Asymptomatic carotid artery (ICA) stenosis

Background1,2
Primary Prevention
Carotid endarterectomy (CEA) is still a matter of controversy in asymptomatic individuals RRR for stenosis >60%NASCET is 38-53% ARR is 5.9-12.6%
NNT to avoid one stroke/year is 63-166

The combined surgical risk must not exceed 3%
1: ACAS: JAMA (1995) 273:1421-8. 2: ACST: Lancet (2004) 363:1491-1502
Asymptomatic carotid artery (ICA) stenosis

Specific issues
Primary Prevention
No prospective trials tested the benefit of antiplatelet drugs in patients with asymptomatic carotid stenosis1 The ipsilateral stroke risk increases with the degree of the stenosis2
Patients with an occlusion of the contralateral ICA do not benefit from endarterectomy3
Women have lower benefit from CEA than men3
Aspirin reduces stroke risk during and after CEA4

1: Chambers BR et al.: Cochrane Review (2005) 2: ECST Group: Lancet (1995) 345:209-12 3: Baker WH et al.: Stroke (2000) 31:2330-4 4: Engelter S et al.: Cochrane Reviews (2003)
Carotid Surgery and Angioplasty

Recommendations
Primary Prevention
Carotid surgery is not recommended for asymptomatic individuals with significant carotid stenosis (NASCET 6099%), except in those at high risk of stroke (Class I, Level C)
Carotid angioplasty, with or without stenting, is not recommended for patients with asymptomatic carotid stenosis (Class IV, GCP)
Patients should take aspirin before and after CEA (Class I, Level A)
Secondary Prevention
Content
Management of vascular risk factors Antithrombotic therapy Surgery and angioplasty
Blood pressure control

Background
Antihypertensive drugs reduce stroke recurrence risk after stroke or TIA (RR 0.76; 95%CI 0.63-0.92)1 Target BP level and reduction should be individualized The reduction in stroke occurs regardless of baseline BP and type of stroke2
1: Rashid P et al.: Stroke (2003) 34:2741-8 2: PROGRESS group: Lancet (2001) 358:1033-41
Diabetes mellitus
Background
In people with type 2 diabetes with previous stroke pioglitazone reduces fatal or nonfatal stroke (HR 0.53; 95%CI 0.34-0.85; P=0.0085)1 In addition there is a trend to reduce the combined end point of death and major vascular events (HR 0.78; 95%CI 0.60-1.02; P=0.067)1
1: Wilcox R et al.: Stroke (2007) 38:865-73
High Cholesterol
Background
Atorvastatin (80mg) reduces stroke recurrence by 16%1 Simvastatin (40mg) reduces risk of vascular events in patients with prior stroke, and of stroke in patients with other vascular disease (RR 0.76)2 ARR for statin treatment is low (NNT 112-143 for 1 year)1 Statin withdrawal at the acute stage of stroke may be harmful3
1: Amarenco P et al.: N Engl J Med (2006) 355:549-559 2: Heart Protection Study: Lancet (2002) 360:7-22 3: Blanco M et al.: Neurology (2007) 69:904-10
Vitamins
Background
Beta carotene increased the risk (RR 1.10) of cardiovascular death1 Antioxidant supplements may increase mortality2 Folate, B12, B6 vitamins given to lower homocysteine levels may not reduce stroke recurrence and may increase vascular events3
1: Vivekananthan D et al.: Lancet (2003) 361:2017-2023 2: Bjelakovic G et al.: JAMA (2007) 297:842-857 3: Bonaa K et al.: N Engl J Med (2006) 354:1578-1588
Hormone Replacement Therapy

Background
Oestrogen therapy is not effective in secondary prevention after TIA or stroke and may increase stroke severity1
1: Viscoli CM et al.: N Engl J Med (2001) 345:1243-9.
Sleep-disordered Breathing
Background
Sleep-disordered breathing (SDB) is both a risk factor and a consequence of stroke More than 50% of stroke patients have SDB, mostly in the form of obstructive sleep apnoea (OSA).
SDB is linked with poorer long-term outcome and increased long-term stroke mortality1
Continuous positive airway pressure is the treatment of choice for OSA.
1: Bassetti CL: Semin Neurol (2005) 25:19-32

Blood pressure should be checked regularly. Blood pressure lowering is recommended after the acute phase, including in patients with normal blood pressure (Class I, Level A)
Blood glucose should be checked regularly. Diabetes should be managed with lifestyle modification and individualized pharmacological therapy (Class IV, GCP)
In patients with type 2 diabetes who do not need insulin, treatment with pioglitazone is recommended after stroke (Class III, Level B)

Statin therapy is recommended (Class I, Level A) Cigarette smoking should be stopped (Class III, Level C) Heavy use of alcohol should be discouraged (Class IV, GCP)
Regular physical activity is recommended (Class IV, GCP)

A diet low in salt and saturated fat, high in fruit and vegetables, and rich in fibre is recommended (Class IV, GCP)

Subjects with an elevated body mass index are recommended to take a weight-reducing diet (Class IV, Level C) Antioxidant vitamins supplements are not recommended (Class I, Level A) Hormone replacement therapy is not recommended for the secondary prevention of stroke (Class I, Level A) Sleep-disordered breathing such as obstructive sleep apnoea is recommended to be treated with continuous positive airway pressure breathing (Class III, Level GCP)
Background: Aspirin
13% relative risk reduction for stroke after TIA or stroke1 Most widely studied dosages of aspirin are 50-150mg The incidence of GI-disturbances with aspirin is dose dependent No difference in effectiveness amongst low (< 160mg), medium (160 325mg) or high (500 - 1500mg) dose aspirin
1: Antithrombotic Trialists' Collaboration: BMJ (2002) 324:71-86
Background: Dipyridamole plus aspirin
Relative risk reduction of vascular death, stroke or myocardial infarction with the combination is significantly greater (RR 0.82; 95%CI 0.71-0.91) than with aspirin alone1,2
ARR 1.0% per year (NNT 100)2

Incidence of dipyridamole induced headache may be reduced by increasing the dose gradually3
1: Diener HC et al.: J Neurol Sci (1996) 143:1-13 2: Halkes P et al.: Lancet (2006) 367:1665-1673 3: Chang YJ et al.: Cerebrovasc Dis (2006) 22:258-62
Dipyridamole plus aspirin versus aspirin: Meta-analysis1
Reduced vascular endpoint (vascular death, stroke, myocardial infarction) with dipyridamole plus aspirin
1: Halkes P et al.: Lancet (2006) 367:1665-1673
Background: Clopidogrel:
Clopidogrel is slightly but significantly more effective than medium-dose aspirin (RRR 8.7%, ARR 0,5%) in preventing vascular events in patients with previous stroke, MI or PAD1
1: CAPRIE Steering Committee: Lancet (1996) 348:1329-1339
Background: Clopidogrel plus aspirin
Compared with clopidogrel the combination of aspirin and clopidogrel does not reduce the risk of ischaemic stroke, myocardial infarction, vascular death, or rehospitalisation1
Compared with aspirin alone the combination does not reduce the risk of myocardial infarction, stroke, or cardiovascular death2
Risk of life-threatening increased1,2
1: Diener H et al.: Lancet (2004) 364:331-337 2: Bhatt D et al.: N Engl J Med (2006) 354:1706-1717
or
major
bleeding
is
Patients should receive antithrombotic therapy (Class I, Level A) Patients not requiring anticoagulation should receive antiplatelet therapy (Class I, Level A). Where possible, combined aspirin and dipyridamole, or clopidogrel alone, should be given. Alternatively, aspirin alone, or triflusal alone, may be used (Class I, Level A)
The combination of aspirin and clopidogrel is not recommended in patients with recent ischaemic stroke, except in patients with specific indications (e.g. unstable angina or non-Q-wave MI during the last 12 months, or recent stenting); treatment should be given for up to 9 months after the event (Class I, Level A) Patients who have a stroke on antiplatelet therapy should be re-evaluated for pathophysiology and risk factors (Class IV, GCP)
Anticoagulation
Background
Oral antiocoagulation (target INR 2.0 3.0) reduces the risk of recurrent stroke in patients with AF1 Oral anticoagulation is well established for other causes of embolism such as mechanical prosthetic valve replacement, rheumatic valvular heart disease, ventricular aneurysm and cardiomyopathy There is no indication for oral anticoagulation in patients with non-cardiac cause of ischaemic stroke2
1: EAFT Study Group: Lancet (1993) 342:1255-1262 2: Mohr JP et al.: N Engl J Med (2001) 345:1444-1451
Anticoagulation
Specific issues
In patients with AF and stable coronary disease, aspirin should not be added to oral anticoagulation1 Some retrospective studies suggest that anticoagulation may be beneficial in aortic atheroma2, fusiform basilar artery aneurysms3, or arterial dissection4 It is unclear if patients with patent foramen ovale (PFO) benefit from oral anticoagulation5
1: Flaker GC et al.: Am Heart J (2006) 152:967-73 2: Dressler FA et al.: J Am Coll Cardiol (1998) 31:134-8 3: Echiverri HC et al.: Stroke (1989) 20:1741-7 4: Engelter ST et al.: Stroke (2007) 38:2605-11 5: Mas JL et al.: N Engl J Med (2001) 345:1740-6
Anticoagulation should not be used after non-cardioembolic ischaemic stroke, except in some specific situations, such as aortic atheromas, fusiform aneurysms of the basilar artery, cervical artery dissection, or patent foramen ovale in the presence of proven deep vein thrombosis (DVT) or atrial septal aneurysm (Class IV, GCP) If oral anticoagulation is contraindicated, combined low dose aspirin and dipyridamole should be given (Class IV, GCP)
Oral anticoagulation (INR 2.03.0) is recommended after ischaemic stroke associated with AF (Class I, Level A). Oral anticoagulation is not recommended in patients with co-morbid conditions such as falls, poor compliance, uncontrolled epilepsy, or gastrointestinal bleeding (Class III, Level C). Increasing age alone is not a contraindication to oral anticoagulation (Class I, Level A) Patients with cardioembolic stroke unrelated to AF should receive anticoagulants (INR 2.0-3.0) if the risk of recurrence is high (Class III, Level C)
Carotid Endarterectomy (CEA)

Background1,2
CEA reduces the risk by 48% of recurrent disabling stroke or death in patients with 70-99%NASCET ipsilateral carotid artery stenosis If perioperative complications exceed 6%, the benefit of CEA will diminish; if it approaches 10%, the benefit will vanish entirely There is also some risk reduction in male patients with 50 - 69% stenosis of the ipsilateral carotid artery, provided that the complication rate is below 3%
1: NASCET Collaborators: NEJM (1991) 325:445-453 2: Warlow C: Lancet (1991) 337:1235-1243 Guidelines Ischaemic Stroke 2008
Carotid Endarterectomy
Specific issues
CEA should be performed as soon as possible (ideally within 2 weeks) after the last cerebrovascular event1,2 Elderly patients (>75 years) without organ failure or serious cardiac dysfunction benefit from CEA1
Women with symptomatic stenosis >70% should undergo CEA. Women with moderate stenosis should be treated medically2
1: Rothwell PM et al.: Lancet (2004) 363:915-924 2: Rothwell PM et al.: Stroke (2004) 35:2855-61
Effect of time from last symptomatic event to randomisation on the 5year relative risk (RR) of ipsilateral ischaemic stroke and any operative stroke or death with CEA (pooled data from ECST and NASCET1)
1: Rothwell PM et al.: Stroke (2004) 35:2855-61
Specific issues
The benefit from CEA is lower with lacunar stroke Patients with leuko-araiosis should be made aware of the increased operative risk Occlusion of the contralateral ICA carries a higher perioperative risk Continuation of aspirin is required until surgery, but heparin may be used in very severe stenosis
All grading of stenoses should be according to NASCET-criteria

Carotid Artery Stenting (CAS)

Background
No randomized trial has demonstrated equivalent periprocedural risk for CAS compared to CEA in treatment of symptomatic carotid artery stenosis A European study only marginally failed to prove the non-inferiority of CAS compared to CEA A French study was stopped prematurely because of a 2.5 fold higher risk of any stroke or death after CAS2
1: Ringleb PA et al.: Lancet (2006) 368:1239-1247 2: Mas JL et al.: NEJM (2006) 355:1660-1671
Carotid Artery Stenting

Metaanalysis CAS vs. CEA Endpoint: any periprocedural stroke or death
1: Kastrup A et al.: Acta Chir Belg (2007) 107:119-28
Intracranial Occlusive Disease

Background
Extracranial-Intracranial bypass is not beneficial in preventing stroke in patients with MCA or ICA stenosis or occlusion1 No randomized controlled trials have evaluated angioplasty, stenting, or both for intracranial stenosis Several non-randomized trials have shown feasibility and acceptable safety of intracranial stenting, but the risk of re-stenosis remains high2,3
1: The EC/IC Bypass Grp: N Engl J Med (1985) 313:1191-200 2: Bose A et al.: Stroke (2007) 38:1531-7 3: SSYLVIA Study investigators: Stroke (2004) 35:1388-92
Surgery and Angioplasty

CEA is recommended for patients with 7099% stenosis (NASCET criteria) (Class I, Level A). CEA should only be performed in centres with a perioperative complication rate (all strokes and death) of less than 6% (Class I, Level A) CEA should be performed as soon as possible after the last ischaemic event, ideally within 2 weeks (Class II, Level B)

CEA may be indicated for certain patients with stenosis of 5069% (NASCET criteria); males with very recent hemispheric symptoms are most likely to benefit (Class III, Level C). CEA for stenosis of 5069% (NASCET criteria) should only be performed in centres with a perioperative complication rate (all stroke and death) of less than 3% (Class I, Level A) CEA is not recommended for patients with stenosis of less than 50% (NASCET criteria) (Class I, Level A)

Patients should remain on antiplatelet therapy both before and after surgery (Class I, Level A) Carotid percutaneous transluminal angioplasty and/or stenting (CAS) is only recommended in selected patients (Class I, Level A). It should be restricted to the following subgroups of patients with severe symptomatic carotid artery stenosis: those with contra-indications to CEA, stenosis at a surgically inaccessible site, re-stenosis after earlier CEA, and post-radiation stenosis (Class IV, GCP)

Patients should receive a combination of clopidogrel and aspirin immediately before and for at least 1 months after stenting (Class IV, GCP) Endovascular treatment may be considered in patients with symptomatic intracranial stenosis (Class IV, GPC)
ESO Guidelines 2008

General Stroke Treatment

Content
Monitoring
General Treatment
Pulmonary and airway care Fluid balance Blood pressure Glucose metabolism Body temperature
Monitoring
Continuous monitoring
Heart rate
General Treatment
Breathing rate O2 saturation
Discontinuous monitoring
Blood pressure Blood glucose Vigilance (GCS), pupils Neurological status (e.g. NIH stroke scale or Scandinavian stroke scale)
Pulmonary function
Background
Adequate oxygenation is important
General Treatment
Improve blood oxygenation by administration of > 2 l O2 Risk for aspiration in patients with side positioning
Hypoventilation may be caused by pathological respiration pattern

Risk of airway obstruction (vomiting, oropharyngeal muscular hypotonia): mechanical airway protection
Blood pressure
Background
Elevated in most patients with acute stroke
General Treatment
BP drops spontaneously during the first days after stroke Blood flow in the critical penumbra passively dependent on the mean arterial pressure There are no adequately sized randomised, controlled studies guiding BP management
Blood pressure
Specific issues
General Treatment
Elevated BP (e.g. up to 200mmHg systolic or 110mmHg diastolic) may be tolerated in the acute phase of ischaemic stroke without intervention BP may be lowered if this is required by cardiac conditions Upper level of systolic BP in patients undergoing thrombolytic therapy is 180mmHg Avoid and treat hypotension Avoid drastic reduction in BP
Glucose metabolism
Background
General Treatment
High glucose levels in acute stroke may increase the size of the infarction and reduce functional outcome Hypoglycemia can mimic acute ischaemic infarction Routine use of glucose potassium insulin (GKI) infusion regimes in patients with mild to moderate hyperglycaemia did not improve outcome1 It is common practise to treat hyperglycemia with insulin when blood glucose exceeds 180mg/dl2 (10mmol/l)
1: Gray CS et al.: Lancet Neurol (2007) 6:397-406 2: Langhorne P et al.: Age Ageing (2002) 31:365-71.
Body temperature
Background
General Treatment
Fever is associated with poorer neurological outcome after stroke Fever increases infarct size in experimental stroke Many patients with acute stroke develop a febrile infection There are no adequately sized trials guiding temperature management after stroke
It is common practice treat fever (and its cause) when the temperature reaches 37.5C

General Treatment
Intermittent monitoring of neurological status, pulse, blood pressure, temperature and oxygen saturation is recommended for 72 hours in patients with significant persisting neurological deficits (Class IV, GCP)
Oxygen should be administered if sPO2 falls below 95% (Class IV, GCP)
Regular monitoring of fluid balance and electrolytes is recommended in patients with severe stroke or swallowing problems (Class IV, GCP)

General Treatment
Normal saline (0.9%) is recommended for fluid replacement during the first 24 hours after stroke (Class IV, GCP) Routine blood pressure lowering is not recommended following acute stroke (Class IV, GCP) Cautious blood pressure lowering is recommended in patients with any of the following; extremely high blood pressures (>220/120 mmHg) on repeated measurements, or severe cardiac failure, aortic dissection, or hypertensive encephalopathy (Class IV, GCP)

General Treatment
Abrupt blood pressure lowering should be avoided (Class II, Level C) Low blood pressure secondary to hypovolaemia or associated with neurological deterioration in acute stroke should be treated with volume expanders (Class IV GCP) Monitoring serum glucose levels is recommended (Class IV, GCP) Treatment of serum glucose levels >180mg/dl (>10mmol/l) with insulin titration is recommended (Class IV, GCP)

General Treatment
Severe hypoglycaemia (<50 mg/dl [<2.8 mmol/l]) should be treated with intravenous dextrose or infusion of 10 20% glucose (Class IV, GCP points) The presence of pyrexia (temperature >37.5C) should prompt a search for concurrent infection (Class IV, GCP) Treatment of pyrexia (>37.5C) with paracetamol and fanning is recommended (Class III, Level C) Antibiotic prophylaxis is not recommended immunocompetent patients (Class II, Level B) in
ESO Guidelines 2008

Specific Stroke Treatment

Content
Thrombolytic therapy
Specific Treatment
Early antithrombotic treatment Treatment of elevated intracranial pressure Prevention and management of complications
Thrombolytic Therapy (i.v. rtPA)

Background (NINDS1, ECASS I2 + II3, ATLANTIS4)
Specific Treatment
Intravenous rtPA (0.9mg/kg, max 90mg) given within 3 hours of stroke onset, significantly improves outcome in patients with acute ischaemic stroke Benefit from the use of i.v. rtPA beyond 3 hours is smaller, but may be present up to at least 4.5 hours Several contraindications
1: NINDS rt-PA Grp: New Engl J Med (1995) 333:1581-1587 2: Hacke W et al.: JAMA (1995) 274:1017-1025 3: Hacke W et al.: Lancet (1998) 352:1245-1251 4: Clark WM et al.: Jama (1999) 282:2019-26.

Specific issues
Specific Treatment
A pooled analysis of the 6 i.v. rtPA trials confirms that i.v. thrombolysis may work up to 4.5 hours1 Caution is advised when considering i.v. rtPA in persons with severe stroke (NIHSSS>25), or if the CT demonstrates extended early infarcts signs Thrombolytic therapy must be given by an experienced stroke physician after the imaging of the brain is assessed by physicians experienced in reading this imaging study2
1: Hacke W et al.: Lancet (2004) 363:768-74 2: Wahlgren N et al.: Lancet (2007) 369:275-82 Guidelines Ischaemic Stroke 2008

Specific issues
Factors associated with increased bleeding risk1
Specific Treatment
elevated serum glucose history of diabetes baseline symptom severity advanced age increased time to treatment previous aspirin use history of congestive heart failure
NINDS protocol violations
None of these reversed the overall benefit of rtPA

1: Lansberg MG et al.: Stroke (2007) 38:2275-8 Guidelines Ischaemic Stroke 2008

Risk and outcome from 6,483 patients of the SITS-Most treated with iv-rtPA within a 3 hour time window1
Specific Treatment
1: Wahlgren N et al.: Lancet (2007) 369:275-82

Mismatch based therapy
Specific Treatment
The use of multimodal imaging criteria may be useful for patient selection1,2 Available data on mismatch, as defined by multimodal MRI or CT, are too limited to guide thrombolysis in routine practice3 Data regarding the use of intravenous desmoteplase administered 3 to 9 hours after acute ischaemic stroke in patients selected on the basis of perfusion/diffusion mismatch are conflicting
1: Khrmann M et al.: Lancet Neurol (2006) 5:661-7 2: Chalela J et al.: Lancet (2007) 369:293-298 3: Kane I et al.: JNNP (2007) 78:485-490
Thrombolytic Therapy (i.a.)

Background: the use of i.a. rtPA, i.a. urokinase
Specific Treatment
Only cases and some prospective uncontrolled case series
Facts: about use of i.a. pro-urokinase

Efficacy demonstrated in small RCT, 6h window1 Not approved and substance not available
1: Furlan A et al.: JAMA (1999) 282:2003-11
Specific Treatment
Specific Treatment
Intravenous rtPA (0.9 mg/kg BW, maximum 90 mg), with 10% of the dose given as a bolus followed by a 60-minute infusion, is recommended within 3 hours of onset of ischaemic stroke (Class I, Level A)
Intravenous rtPA may be of benefit also for acute ischaemic stroke beyond 3 hours after onset (Class I, Level B) but is not recommended for routine clinical practice. The use of multimodal imaging criteria may be useful for patient selection (Class III, Level C)
Specific Treatment
Specific Treatment
Blood pressures of 185/110 mmHg or higher must be lowered before thrombolysis (Class IV, GCP) Intravenous rtPA may be used in patients with seizures at stroke onset, if the neurological deficit is related to acute cerebral ischaemia (Class IV, GCP) Intravenous rtPA may also be administered in selected patients over 80 years of age, although this is outside the current European labelling (Class III, Level C)
Specific Treatment
Specific Treatment
Intra-arterial treatment of acute MCA occlusion within a 6hour time window is recommended as an option (Class II, Level B) Intra-arterial thrombolysis is recommended for acute basilar occlusion in selected patients (Class III, Level B) Intravenous thrombolysis for basilar occlusion is an acceptable alternative even after 3 hours (Class III, Level B)
Antiplatelet therapy
Background
Specific Treatment
Aspirin was tested in large RCTs in acute (<48 h) stroke1,2 Significant reduction was seen in death and dependency (NNT 70) and recurrence of stroke (NNT 140) A phase 3 trial for the glycoprotein-IIb-IIIa antagonist abciximab was stopped prematurely because of an increased rate of bleeding3
1: International-Stroke-Trial: Lancet (1997) 349:1569-1581 2: CAST-Collaborative-Group: Lancet (1997) 349:1641-1649 3: Adams HP, Jr. et al.: Stroke (2007)
Anticoagulation
Unfractionated heparin
No formal trial available testing standard i.v. heparin
Specific Treatment
IST showed no net benefit for s.c. heparin treated patients because of increased risk of ICH1
Low molecular weight heparin

No benefit on stroke outcome for low molecular heparin (nadroparin, certoparin, tinzaparin, dalteparin)
Heparinoid (orgaran)
TOAST trial neutral2
1: International-Stroke-Trial: Lancet (1997) 349:1569-1581 2: TOAST Investigators: JAMA (1998) 279:1265-72.
Neuroprotection
No adequately sized trial has yet shown significant effect in predefined endpoints for any neuroprotective substance A meta-analysis has suggested a mild benefit for citocoline1
Specific Treatment
1: Davalos A et al.: Stroke (2002) 33:2850-7
Specific Treatment
Specific Treatment
Aspirin (160325 mg loading dose) should be given within 48 hours after ischaemic stroke (Class I, Level A) If thrombolytic therapy is planned or given, aspirin or other antithrombotic therapy should not be initiated within 24 hours (Class IV, GCP) The use of other antiplatelet agents (single or combined) is not recommended in the setting of acute ischaemic stroke (Class III, Level C) The administration of glycoprotein-IIb-IIIa inhibitors is not recommended (Class I, Level A)
Specific Treatment
Specific Treatment
Early administration of unfractionated heparin, low molecular weight heparin or heparinoids is not recommended for the treatment of patients with ischaemic stroke (Class I, Level A)
Currently, there is no recommendation to treat ischaemic stroke patients with neuroprotective substances (Class I, Level A)
Elevated Intracranial Pressure

Basic management
Head elevation up to 30
Specific Treatment
Pain relief and sedation Osmotic agents (glycerol, mannitol, hypertonic saline) Ventilatory support Barbiturates, hyperventilation, or THAM-buffer Achieve normothermia Hypothermia may reduce mortality1
1: Steiner T et al.: Neurology (2001) 57(Suppl 2):S61-8.

Malignant MCA/hemispheric infarction
Pooled analysis of three European RCTs (N=93)1,2:
Specific Treatment
Significantly decreases mortality after 30 days Significantly more patients with mRS <4 or mRS <3 in the decompressive surgery group after one year
No increase of patients surviving with mRS=5

Surgery should be done within 48 hours1,2 Side of infarction did affect outcome1,2
Age >50 years is a predictor for poor outcome3

1: Vahedi K et al.: Lancet Neurol (2007) 6:215-22 2: Jttler E et al.: Stroke (2007) 38:2518-25 3: Gupta R et al.: Stroke (2004) 35:539-43

Absolute risk reduction (ARR) and odds ratio (OR) for unfavourable outcome at 12 months: combined analysis of decompression trials1
Specific Treatment
1: Vahedi K et al.: Lancet Neurol (2007) 6:215-22

Specific Treatment
Surgical decompressive therapy within 48 hours after symptom onset is recommended in patients up to 60 years of age with evolving malignant MCA infarcts (Class I, Level A)
Osmotherapy can be used to treat elevated intracranial pressure prior to surgery if this is considered (Class III, Level C)

Specific Treatment
No recommendation can be given regarding hypothermic therapy in patients with space-occupying infarctions (Class IV, GCP) Ventriculostomy or surgical decompression can be considered for treatment of large cerebellar infarctions that compress the brainstem (Class III, Level C)
ESO Guidelines 2008

Management of Complications
Aspiration and pneumonia
Specific Treatment
Bacterial pneumonia is one of the most important complications in stroke patients1 Preventive strategies
Withhold oral feeding until demonstration of intact swallowing, preferable using a standardized test Nasogastric (NG) or percutaneous enteral gastrostomy (PEG) Frequent changes of the patients position in bed and pulmonary physical therapy
Prophylactic administration of levofloxacin is not superior to optimal care2

1: Weimar C et al.: Eur Neurol (2002) 48:133-40 2: Chamorro A et al.: Stroke (2005) 36:1495-500 Guidelines Ischaemic Stroke 2008
Urinary tract infections
Specific Treatment
Most hospital-acquired urinary tract infections are associated with the use of indwelling catheters1 Intermittent catheterization does not reduce the risk of infection
If urinary infection is diagnosed, appropriate antibiotics should be chosen following basic medical principles
1: Gerberding JL: Ann Intern Med (2002) 137:665-70c
Deep vein thrombosis and pulmonary embolism
Specific Treatment
Risk might be reduced by good hydration and early mobilization Low-dose LMWH reduces the incidence of both DVT (OR 0.34) and pulmonary embolism (OR 0.36), without a significantly increased risk of intracerebral (OR 1.39) or extracerebral haemorrhage (OR 1.44)1,2
1: Diener HC et al.: Stroke (2006) 37:139-44 2: Sherman DG et al.: Lancet (2007) 369:1347-55
Pressure ulcer
Specific Treatment
Use of support surfaces, frequent repositioning, optimizing nutritional status, and moisturizing sacral skin are appropriate preventive strategies1
Seizures
Prophylactic anticonvulsive treatment is not beneficial
Agitation
Causal treatment must precede any type of sedation or antipsychotic treatment
1: Reddy M et al.: JAMA (2006) 296:974-84 Guidelines Ischaemic Stroke 2008
Falls
Are common in every stage of stroke treatment
Specific Treatment
Risk factors include cognitive impairment, depression, polypharmacy and sensory impairment1 A multidisciplinary package focusing on personal and environmental factors might be preventive2 Exercise, calcium supplements and bisphosphonates improve bone strength and decrease fracture rates in stroke patients3,4
1: Aizen E et al.: Arch Gerontol Geriatr (2007) 44:1-12 2: Oliver D et al.: BMJ (2007) 334:82 3: Pang MY et al.: Clin Rehabil (2006) 20:97-111 4: Sato Y et al.: Cerebrovasc Dis (2005) 20:187-92
Dysphagia and feeding
Specific Treatment
Dysphagia occurs in up to 50% of patients with unilateral hemiplegic stroke and is an independent risk-factor for poor outcome1 For patients with continuing dysphagia, options for enteral nutrition include NG or PEG feeding PEG does not provide better nutritional status or improved clinical outcome, compared to NG2,3
1: Martino R et al.: Stroke (2005) 36:2756-63 2: Dennis MS et al.: Lancet (2005) 365:764-72 3: Callahan CM et al.: J Am Geriatr Soc (2000) 48:1048-54
Specific Treatment
Infections after stroke should be treated with appropriate antibiotics (Class IV, GCP) Prophylactic administration of antibiotics is not recommended, and levofloxacin can be detrimental in acute stroke patients (Class II, Level B) Early rehydration and graded compression stockings are recommended to reduce the incidence of venous thromboembolism (Class IV, GCP) Early mobilization is recommended to prevent complications such as aspiration pneumonia, DVT and pressure ulcers (Class IV, GCP) Guidelines Ischaemic Stroke 2008
Specific Treatment
Low-dose s.c. heparin or low molecular weight heparins should be considered for patients at high risk of DVT or pulmonary embolism (Class I, Level A) Administration of anticonvulsants is recommended to prevent recurrent seizures (Class I, Level A) Prophylactic administration of anticonvulsants to patients with recent stroke who have not had seizures is not recommended (Class IV, GCP) An assessment of falls risk is recommended for every stroke patient (Class IV, GCP)
Specific Treatment
Calcium/vitamin-D supplements are recommended in stroke patients at risk of falls (Class II, Level B) Bisphosphonates (alendronate, etidronate and risedronate) are recommended in women with previous fractures (Class II, Level B) In stroke patients with urinary incontinence, specialist assessment and management is recommended (Class III, Level C) Swallowing assessment is recommended but there are insufficient data to recommend a specific approach for treatment (Class III, GCP) Guidelines Ischaemic Stroke 2008
Specific Treatment
Oral dietary supplements are only recommended for nondysphagic stroke patients who are malnourished (Class II, Level B) Early commencement of nasogastric (NG) feeding (within 48 hours) is recommended in stroke patients with impaired swallowing (Class II, Level B) Percutaneous enteral gastrostomy (PEG) feeding should not be considered in stroke patients in the first 2 weeks (Class II, Level B)
ESO Guidelines 2008

Rehabilitation
Early rehabilitation
Rehabilitation
More than 40 % of stroke patients need active rehabilitation Active rehabilitation should start early, providing the patient is clinically stable
Passive rehabilitation should be given if the patient is unconscious or paralysed

Rehabilitation should be continued as long as perceptable recovery is taking place
Rehabilitation
Multidisciplinary stroke team for rehabilitation
Stroke physician
Rehabilitation
Nurses experienced in stroke management Physiotherapist trained in stroke rehabilitation Occupational therapist skilled in stroke Speech therapist familiar with speech problems in stroke patients Neuropsychologist accustomed to stroke rehabilitation
Social worker familiar with the problems of stroke patients

Setting of Rehabilitation
Rehabilitation
Admission to a stroke unit is recommended for acute stroke patients to receive coordinated multidisciplinary rehabilitation (Class I, Level A) Early discharge from stroke unit care is possible in medically stable patients with mild or moderate impairment providing that rehabilitation is delivered in the community by a multidisciplinary team with stroke expertise (Class I, Level A)
Setting of Rehabilitation
Rehabilitation
Rehabilitation should be continued after discharge during the first year after stroke (Class II, Level A) Early initiation of rehabilitation is recommended (Class III, Level C)
It is recommended that the duration and intensity of rehabilitation is increased (Class II, Level B)
Elements of Rehabilitation
Rehabilitation
Physiotherapy is recommended, but the optimal mode of delivery is unclear (Class I, Level A) Occupational therapy is recommended, but the optimal mode of delivery is unclear (Class I, Level A)
While assessment for communication deficits is recommended, there are insufficient data to recommend specific treatments (Class III, GCP)
Information should be provided to patient and carers but evidence does not support use of a dedicated stroke liaison service for all patients (Class II, Level B)
Rehabilitation
Rehabilitation must be considered for all stroke patients, but there is limited evidence to guide appropriate treatment for the most severely disabled (Class II, Level B)
While assessment for cognitive deficits appears desirable, there are insufficient data to recommend specific treatments (Class I, Level A)
Patients should be monitored for depression during hospital stay and throughout follow up (Class IV, Level B)
Rehabilitation
Drug therapy and non-drug interventions recommended to improve mood (Class I, Level A)
are
Drug therapy should be considered to treat post stroke emotionalism (Class II, Level B)
Tricyclic or anticonvulsant therapy are recommended to treat post-stroke neuropathic pain in selected patients (Class III, Level B)
Botulinum toxin should be considered to treat post-stroke spasticity, but functional benefits are uncertain (Class III, Level B)

ESO08 Slides 25thapril

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

ESO08 Slides 25thapril

Uploaded by

Copyright:

Available Formats

Guidelines for Management of Ischaemic Stroke 2008

Guidelines Ischaemic Stroke 2008

ESO Guidelines 2008

ESO Writing Committee

Co-Chairs: Marie-Germaine Bousser, Paris, France Gary Ford, Newcastle, UK

Guidelines Ischaemic Stroke 2008

ESO Writing Committee

ESO Writing Committee

ESO Writing Committee

ESO Writing Committee

Guidelines Ischaemic Stroke 2008

Definitions of Levels of Evidence

Good Clinical Practice (GCP)

Guidelines Ischaemic Stroke 2008

ESO Guidelines 2008

Guidelines Ischaemic Stroke 2008

The delay between stroke onset and hospital admission is;

Emergency care in acute stroke depends on a four-step chain:

Priority transport with notification of the receiving hospital

1:Kwan J et al. Age Ageing (2004) 33:116-121

Guidelines Ischaemic Stroke 2008

Guidelines Ischaemic Stroke 2008

Time is the most important factor

Guidelines Ischaemic Stroke 2008

The initial examination should include

Blood samples for clinical chemistry, coagulation and haematology studies

Targeted neurological examination

Ancillary Diagnostic Tests

Hepatic and renal chemical analysis

Guidelines Ischaemic Stroke 2008

Ancillary Diagnostic Tests

Guidelines Ischaemic Stroke 2008

Guidelines Ischaemic Stroke 2008

ESO Guidelines 2008

1:Langhorne P et al. Age Ageing (2002) 31:365-371

Guidelines Ischaemic Stroke 2008

Typical components of stroke units include

Treatment at a stroke unit compared to treatment in a general ward1

1:Stroke Unit Trialists' Collaboration Cochrane Rev (2007)

Guidelines Ischaemic Stroke 2008

Stroke Services and Stroke Units

Guidelines Ischaemic Stroke 2008

ESO Guidelines 2008

Emergency Diagnostic Tests

Guidelines Ischaemic Stroke 2008

Emergency Diagnostic Tests

Detects signs of ischaemia as early as 2 h after stroke onset1

Helps to identify other neurological diseases (e.g. neoplasms)

Guidelines Ischaemic Stroke 2008

Emergency Diagnostic Tests

MRI is particularly important in acute stroke patients with unusual presentations

Emergency Diagnostic Tests

Emergency Diagnostic Tests

It is therefore applicable to patients unable to cooperate with MRA or CTA1

Guidelines Ischaemic Stroke 2008

Emergency Diagnostic Tests

Guidelines Ischaemic Stroke 2008

Emergency Diagnostic Tests

Arrhythmias may induce stroke, stroke may cause arrhythmias

Emergency Diagnostic Tests

Emergency Diagnostic Tests

Guidelines Ischaemic Stroke 2008